Praveg Ltd reported a consolidated net loss of Rs 20.13 crore for the September 2026 quarter, up from Rs 9.22 crore a year ago. Despite revenue growth, rising costs pressured the bottom line. The company also announced a change in its Company Secretary and is awaiting BSE approval for a debt-to-equity conversion and a preferential warrant issue.
Praveg Ltd Q2 Net Loss Widens to Rs 20.13 Crore
Revenue grew to Rs 43.75 crore from Rs 39.39 crore in Q2 FY2026, while the net loss expanded to Rs 20.13 crore.
Reader Takeaway: Revenue growth is being outpaced by rising costs, alongside critical pending debt-to-equity conversions and leadership changes.
What just happened
Praveg Ltd has released its financial results for the quarter ended September 30, 2026, alongside key updates regarding its management and capital structure. The company recorded a revenue of Rs 43.75 crore for the second quarter, marking an increase from the Rs 39.39 crore reported in the same period last year. However, net losses deepened significantly to Rs 20.13 crore, compared to a net loss of Rs 9.22 crore in the prior year quarter.
Why this matters
The company's inability to convert revenue growth into profitability remains a primary concern for investors. With half-yearly losses now at Rs 33.37 crore versus Rs 14.97 crore previously, cost management is becoming a critical hurdle. Additionally, the company is undergoing leadership transitions, with Himalay Amardas Dudharejiya taking over as Company Secretary and Compliance Officer from November 3, 2026, following the resignation of Mukeshkumar Sohanram Chaudhary.
What changes now
Praveg Ltd is currently awaiting in-principle approval from the BSE for significant corporate actions. This includes the conversion of an unsecured inter-corporate loan from Jhaveri Credits and Capital Limited into 8,33,700 equity shares. Furthermore, the firm has proposed the issuance of 11,00,000 convertible warrants to the promoter group, a move that will impact equity dilution once approved.
Risks to watch
The primary risk remains the widening net loss, which could continue to strain cash flow and balance sheet health. The outcome of the pending regulatory approvals for the preferential issue and debt conversion will determine future liquidity and the extent of shareholder dilution.
What to track next
Investors should monitor the company's ability to stabilize operating costs and the final timeline for the BSE approvals regarding the proposed equity and warrant issuance.